Protein modification by the degradation products of ascorbate: formation of a novel pyrrole from the Maillard reaction of L-threose with proteins.
Ascorbate (vitamin C) degradation products can undergo non-enzymatic glycation (Maillard reaction) with proteins to form highly crosslinked structures with brown pigmentation and characteristic fluorescence. Proteins in the body, especially the long-lived proteins develop similar changes during aging and diabetes. Several studies have shown excessive degradation of ascorbate in plasma in diabetes, and in ocular lens during aging and cataract formation. Recent studies have suggested that ascorbate degradation products-mediated glycation plays a role in lens pigmentation and cataract formation. However, the precise chemical nature of ascorbate-specific advanced glycation end-products are not known. Here, we report the purification and characterization of a glycation end-product derived from one of the major degradation products of ascorbate, L-threose. This compound was characterized to be 2-acetamido-6-(3-(1,2-dihydroxyethyl)-2-formyl-4-hydroxymethyl-1- pyrrolyl)hexanoic acid (formyl threosyl pyrrole or FTP) formed by the condensation of epsilon-amino group of lysine with two molecules of threose. Formation of FTP occurred rapidly in the incubation of threose and lysine and reached plateau level within a day. We have developed a sensitive assay for its quantification in proteins based on enzyme digestion followed by HPLC. Ribonuclease A and human lens crystallins incubated with L-threose showed time- and sugar concentration-dependent increases in FTP, reaching 8.2 and 2.48 nmol per mg protein, respectively after one week of incubation. Human plasma proteins showed a peak with identical retention time as that of purified FTP under two different HPLC conditions. FTP may be used as a sensitive marker to assess ascorbate-mediated protein glycation and modifications in aging and diabetes.
D000614:Aminocaproates; D001120:Arginine / Q000031:analogs & derivatives / Q000737:chemistry; D001798:Blood Proteins / Q000737:chemistry; D002208:Caproates / Q000737:chemistry*; D002851:Chromatography, High Pressure Liquid; D003094:Collagen / Q000737:chemistry; D003432:Cross-Linking Reagents / Q000737:chemistry; D003459:Crystallins / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood; D005453:Fluorescence; D017127:Glycation End Products, Advanced / Q000737:chemistry*; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives / Q000737:chemistry; D009682:Magnetic Resonance Spectroscopy; D015416:Maillard Reaction; D013058:Mass Spectrometry; D008956:Models, Chemical; D011506:Proteins / Q000737:chemistry*; D011758:Pyrroles / Q000737:chemistry*; D012259:Ribonuclease, Pancreatic / Q000737:chemistry; D013053:Spectrophotometry; D013780:Tetroses / Q000737:chemistry*
C096999:2-acetamido-6-(4-(1,2-dihydroxyethyl)-2-formyl-3-hydroxymethyl-1-pyrrolyl)hexanoic acid; D000614:Aminocaproates; D001798:Blood Proteins; D002208:Caproates; D003432:Cross-Linking Reagents; D003459:Crystallins; D017127:Glycation End Products, Advanced; D011506:Proteins; D011758:Pyrroles; D013780:Tetroses; C002315:N(alpha)-acetyllysine; D003094:Collagen; D001120:Arginine; C062187:pentosidine; D012259:Ribonuclease, Pancreatic; D008239:Lysine; C073321:erythrose